Publications by authors named "L Scarfo"
Article Synopsis
- - The study analyzed 3306 patients in Italy with relapsed/refractory chronic lymphocytic leukemia (CLL) treated with ibrutinib, showing a median follow-up of 42.2 months and a median age of 72.1 years, with 42.6% having undergone at least two prior treatments.
- - 24-month survival probabilities indicated that 57.9% of patients remained on treatment and alive, while the median time to treatment discontinuation was 31.3 months; factors like age, performance status, and genetic mutations impacted treatment outcomes.
- - The findings suggest that ibrutinib is generally effective for R/R CLL, but certain patient characteristics, particularly genetic factors, correspond
Article Synopsis
- The study investigates a chemotherapy-free treatment combining atezolizumab, venetoclax, and obinutuzumab for patients with diffuse large B-cell lymphoma variant of Richter transformation, which is known for being difficult to treat and having a poor prognosis.
- It was a phase 2, multicenter trial involving 15 hospitals across Italy and Switzerland, targeting patients with a specific type of cancer transformation after certain prior conditions.
- The primary goal was to achieve an overall response rate of at least 67% by day 21 of cycle 6, with the study being registered under ClinicalTrials.gov, NCT04082897, and completed by October 2022.*
SF3B1 mutations are recurrent in chronic lymphocytic leukemia (CLL), particularly enriched in clinically aggressive stereotyped subset #2. To investigate their impact, we conducted RNA-sequencing of 18 SF3B1 and 17 SF3B1 subset #2 cases and identified 80 significant alternative splicing events (ASEs). Notable ASEs concerned exon inclusion in the non-canonical BAF (ncBAF) chromatin remodeling complex subunit, BRD9, and splice variants in eight additional ncBAF complex interactors.
View Article and Find Full Text PDF